For a lot of people, sex changes somewhere in their forties or fifties and nobody quite explains why. Lubrication drops off, penetration starts to sting, arousal takes longer to arrive, and orgasm — sometimes — feels like more effort than it used to. Then the appointment ends with "that's menopause" and no plan.

There is a plan, in most cases. But the useful advice depends on separating three things the word "menopause" lumps together: tissue changes that are genuinely treatable, symptoms that are treatable but indirect, and the parts that are ordinary variation rather than a hormone problem. This article is about telling those apart. It is not medical advice, and nothing here is a reason to change a prescription.

What is actually changing

The best-established change is in the tissue itself. Falling oestrogen thins and dries the vulva and vagina, reduces elasticity, and slows the natural lubrication response. That cluster has a name — genitourinary syndrome of menopause (GSM) — and the North American Menopause Society's 2020 position statement is blunt about two things: it is chronic and progressive rather than something that settles on its own, and it is routinely under-recognised and under-treated (NAMS, 2020).

Around that sit the symptoms that get all the attention: hot flushes and night sweats, which fragment sleep, and broken sleep on its own is enough to flatten desire and energy. Add the life context that often arrives at the same time — relationship changes, caring responsibilities, career pressure, body-image shifts — and the picture is rarely one hormone.

This is where the popular story goes wrong. "Menopause means low libido" is tidy and mostly false as a general rule: circulating hormone levels map poorly onto desire from one person to the next. What holds up much better is the tissue story. Comfort and lubrication change predictably; desire changes variably.

How this touches orgasm specifically

GSM acts mostly on arousal and comfort, not on the orgasm reflex itself. That distinction matters, because it points at what will actually help. If penetration hurts, the whole experience changes shape: you brace, arousal drops, reaching orgasm gets harder. Treat the pain and the rest often follows without anything being done to orgasm.

Some people do report genuinely weaker or slower orgasms. It's a common experience, but it is worth knowing how much the research can actually support. Most menopausal sexual-function studies use composite questionnaires that roll desire, arousal, lubrication, orgasm, satisfaction and pain into a single score. A better score is real and meaningful; it is not the same as evidence that orgasm changed on its own. Anyone claiming otherwise is reading more into the data than is there — including us, which is why this section is short.

What the evidence supports

  • Local vaginal oestrogen. The first-line treatment for GSM in most guidelines, and effective for dryness, pain and recurrent urinary symptoms. At licensed doses systemic absorption is low. It works on tissue, so it tends to improve comfort first and everything downstream second.
  • Ospemifene. An oral selective oestrogen receptor modulator that improved sexual-function scores against placebo in postmenopausal women with vulvar and vaginal atrophy. A real option for people who can't or would rather not use vaginal oestrogen — as a prescription, with its own risk profile.
  • Systemic menopausal hormone therapy. Effective for vasomotor symptoms and GSM. Its effect on sexual function is modest and mostly arrives by proxy — better sleep, less dryness, fewer flushes.
  • Testosterone. The honest version: a Cochrane review found small improvements in sexual-function scores in postmenopausal women, with real uncertainty, androgenic side effects, and no licence for women in many countries. It is a conversation to have with a clinician who knows the evidence, not a self-directed experiment.
  • Lubricants and moisturisers. Unglamorous, immediately useful, and worth trying before anything prescription. A lubricant for the moment, a moisturiser used regularly for baseline comfort — they are different products and do different jobs.
  • Pelvic floor physiotherapy. Some trials show benefit for sexual function and for pain. It is also the right referral if penetration has become painful or tight rather than merely dry.
  • Reviewing what else you take. SSRIs, some blood-pressure drugs and hormonal contraception all affect orgasm. If a change tracks a prescription rather than a life stage, that is worth ruling out first — see medication and orgasm.

What is not established

A lot is sold to this audience on very thin evidence. "Hormone balancing" supplements, proprietary blends and most over-the-counter libido products have weak or absent trial support. Compounded "bioidentical" hormones are not the same thing as regulated menopausal hormone therapy, and the difference is not cosmetic. And the framing to be wary of is restoration — the promise that the right intervention gets you back to exactly how you were. Bodies change. The realistic aim is comfort and pleasure, not a number from a decade ago.

How to tell what's changing for you

Perimenopause is erratic by definition — cycles stretch and shorten, symptoms come and go — so a single bad month tells you almost nothing. What does tell you something is keeping the parts separable over a couple of months: whether penetration hurt, whether lubrication was there, what method you used, whether you reached orgasm and how intense it felt, how you slept, and any change in medication or hormones. Patterns show up in that set long before they are obvious in memory.

Compare against your own earlier baseline rather than against anyone else's average. Averages hide enormous individual variation, which is exactly why the global statistics page publishes only what clears a minimum sample size and refuses to show anything smaller — useful for the shape of a population, useless as a target for one person.

When to see a clinician

  • Any bleeding after menopause needs prompt assessment. Not "mention it next time" — book it.
  • Pain that is new, persistent, or stops you having sex. This is treatable and it is not something to endure.
  • Distress. If it is bothering you, that is sufficient reason to raise it. "It's just menopause" is not an answer.
  • Ask specifically about GSM and local oestrogen. The NAMS statement exists largely because this is missed. Naming the condition tends to move the conversation forward.
  • Bring the data. Three months of notes about pain, lubrication and intensity is a far more useful opening than "things feel different", and it makes the before/after of any treatment visible.

None of this is medical advice, and it is not a substitute for a clinician who knows your history. If something has changed suddenly, or you have pain or bleeding, that is a conversation to have with a doctor rather than with a tracking app.

Sources

  1. The NAMS 2020 GSM Position Statement Editorial Panel (2020). The 2020 genitourinary syndrome of menopause position statement. Menopause, 27(9), 976–992. (doi:10.1097/GME.0000000000001609. The consensus statement on vulvovaginal changes after menopause, including that the condition is chronic, progressive and under-treated.) https://pubmed.ncbi.nlm.nih.gov/32852449/
  2. Constantine, G., Graham, S., Portman, D. J., Rosen, R. C., & Kingsberg, S. A. (2015). Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric, 18(2), 226–232. (doi:10.3109/13697137.2014.954996. An oral selective oestrogen receptor modulator improved sexual-function scores against placebo — an option for people who cannot or prefer not to use vaginal oestrogen.) https://pubmed.ncbi.nlm.nih.gov/25252699/
  3. Somboonporn, W., Davis, S., Seif, M. W., & Bell, R. (2005). Testosterone for peri- and postmenopausal women. Cochrane Database of Systematic Reviews, (4), CD004509. (doi:10.1002/14651858.CD004509.pub2. A Cochrane review. Small improvements in sexual-function scores, with real uncertainty and androgenic side effects — and it is not licensed for women in many countries.) https://pubmed.ncbi.nlm.nih.gov/16235365/
  4. Cucinella, L., Cassani, C., Martini, E., Parrotta, G. E., et al. (2025). Sexual function after menopause: the role of vaginal estrogens. Maturitas, 200, 108681. (doi:10.1016/j.maturitas.2025.108681. A recent review of local oestrogen therapy and sexual function after menopause.) https://pubmed.ncbi.nlm.nih.gov/40743861/